FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET Â | Source: FibroBiologics, Inc. Advancing preparations to…
Bright Minds Biosciences toPresent at Upcoming Conferences
October 30, 2025 18:30 ET Â | Source: Bright Minds Biosciences NEW YORK,…
South Korea’s Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025
AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL,…
Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
Berlin Heals Welcomes Dr. Eric Fain as New Board Member
Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors…
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025 07:00 ET Â | Source: Sagimet Biosciences Inc. Denifanstat met…
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ --Â Halia Therapeutics, Inc., a clinical-stage biopharmaceutical…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),…